MedTrace Logo

[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis

NCT02880995 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-09-25

No results posted yet for this study

Summary

The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders. And the second purpose of this study is to determine the potential of \[18 fluorine(F)\]-DOPA to be used to predict treatment response to antipsychotic treatment in first episode psychosis.

Conditions

Interventions

DEVICE

PET scan

The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.

BEHAVIORAL

clinical scale

Patient group should complete clinical scales at baseline and 6 week.

DRUG

6 weeks of treatment with amisulpride

The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Euitae Kim, Ph. D. · Seoul National University Bundang Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880995 on ClinicalTrials.gov